Brain Tumours: Research and Treatment

Helen Morgan Excerpts

Thursday 8th May 2025 Commons Chamber

[Helen Morgan (North Shropshire) (LD)]

I thank the hon. Member for Mitcham and Morden (Dame Siobhain McDonagh) and my hon. Friend the Member for Witney (Charlie Maynard) for bringing forward this debate. It has been a privilege to sit through such excellent speeches on this very important topic. I am sure that the hon. Lady’s sister Margaret would be very proud of her, and I am sure that my hon. Friend’s sister is proud of him too.

As the hon. Lady and my hon. Friend have outlined, a brain tumour diagnosis can be utterly devastating and life-changing. Some 12,000 people a year are diagnosed with a primary tumour, while many others are diagnosed with a secondary tumour that has spread from elsewhere in their body. Primary tumours are largely unpreventable, and cause the death of more adults and children under 40 than any other type of cancer. As primary brain tumours do not spread around the body like other cancer types, they do not receive the same staging categorisation.

Current NHS programmes for diagnosing cancers earlier do not include brain tumours, as they focus on targets and improvements for catching more cancers in stages 1 and 2. Nearly half of people diagnosed—49%—are found to have a so-called benign tumour, a grade 1 or 2 tumour that grows more slowly. Those tumours are not technically cancerous, so they are not covered by previous cancer plans or initiatives for improving cancer care. However, the treatment and care for patients with a low-grade tumour has long-lasting impacts and can be life-altering.

I would like to mention the experience of my constituent Madi Ruby, who has tirelessly campaigned and fundraised on this issue. She has experienced both a grade 1 and a grade 2 tumour. She first experienced symptoms of a brain tumour in 1995 with numbness in her right arm, and went on to write backwards and develop headaches. She went for a CT scan when that numbness spread to her foot and she was involved in a minor car accident. Only then was she diagnosed with a grade 1 meningioma measuring 6 cm, which was removed—she was only 23 at the time.

Although that surgery was successful, Madi developed partial epilepsy. She was eventually discharged after five years of clear scans, but as we have heard, tumours still impact lives. She has had poor mental health and become depressed, and in 2013, her brain tumour returned. That tumour has also been removed, but she still deals with partial epilepsy, constant headaches and migraines, and suffers daily. She is also an inspirational person; she has bravely spoken out about her depression, trained to be a counsellor, and is now an associate dean responsible for nursing and allied health professionals at Wrexham Glyndŵr University.

I also want to mention my constituent Shaun Burgess, who raised more than £11,000 for the Brain Tumour Charity and the Meningioma Support Group by running 3,000 miles across Shropshire last year. He was raising money after his wife Mo was treated for a non-cancerous tumour, but not everyone diagnosed with a brain tumour gets that second chance; Shaun has lost a friend to a more aggressive brain tumour.

We must end the tragedy of people losing their lives because treatment for brain cancer took too long to start. As my hon. Friend the Member for Witney has outlined, progress on the treatment of brain tumours has not been good enough. The diagnosis and treatment of cancer should be a top priority for any Government, and the UK should be a global leader in cancer research and outcomes. I urge the Minister to listen to the pleas of Members from across the House on that point today.

For so many people, diagnosis and treatment are too difficult to access. My constituency is a typical example. The major hospitals in Shrewsbury and Telford face a number of challenges and regularly have some of the longest waiting times in the NHS for cancer screening and treatment. In December 2024, just 64% of patients were treated within the 62-day period, despite the target being 85%. The average across England was much better, but still poor at 71%.

Not only do too many people live in treatment deserts, but when they are finally offered the treatment they need, it is hard to access. Anyone living in rural North Shropshire would say that. Having waited anxiously for weeks or months for a scan and the result, they then, if the news is bad, have to travel extremely long distances for the treatment they need. Most of North Shropshire is an hour and a quarter away from a radiotherapy centre on public transport. For patients with brain tumours, public transport is fundamental if they can no longer drive. One of my constituents has faced exactly that problem, having had their driving licence suspended by the Driver and Vehicle Licensing Agency after being diagnosed with a tumour. Apparently that could be remedied if his consultant provided a BT1 form, but he has not been able to get through to the doctor. In the meantime, he is trapped without freedom in a constituency with some of the worst public transport in the country.

Ongoing funding issues, which we know are a huge challenge for the Government, continue to afflict brain tumour patients in a number of ways. Another constituent of mine told me their experience after being referred to a care navigator following their diagnosis. The care navigator’s job is to contact patients on a monthly basis, seeing whether they have any problems and concerns and guiding them through an experience that is extremely traumatic. However, the care navigator position has now been cut, and my constituent has been left in the dark, with growing anxiety and no one to speak to. No one should be going without treatment because there is not enough equipment, and no one should suffer because there are not enough staff to support them.

What would Liberal Democrats do? We would recruit more cancer nurses, so that every patient has a dedicated specialist supporting them throughout their treatment. For brain tumours, we would like to see an improvement in diagnosis, the care people receive and the range of treatment options available. Diagnosis targets need to reflect the fact that brain cancer does not occur in stages in the way that other cancers do—otherwise, we risk brain tumours falling through the cracks of NHS targets and objectives. Low-grade brain tumours, such as that suffered by Madi, need renewed attention, including in the upcoming cancer plan, which we look forward to seeing.

The Liberal Democrats have committed to boosting cancer survival rates more generally by passing a cancer survival research Act, which would require the Government to co-ordinate and ensure funding for research into the cancers with the lowest survival rates, such as brain tumours. We would halve the time for new treatments to reach patients by expanding the Medicines and Healthcare products Regulatory Agency’s capacity and ensuring that every patient starts their treatment for cancer within that 62-day urgent referral target. We would replace ageing radiotherapy machines and increase their number so that no one has to travel too far for treatment. Measures such as Margaret’s law, which the hon. Members who secured this debate have pressed for, would be an important step in the right direction to improve research in glioblastoma in particular, and I urge the Minister to consider that too.

Do the Government have any future plans for allocating support to research into vaccine treatment for brain tumours, which has reportedly shown remarkable progress against glioblastoma in recent studies? Too many patients with brain tumours have been let down by previous Governments over many years, and I hope that this Government will step up and make brain tumours, cancer and NHS care their No. 1 priority.

[Madam Deputy Speaker (Judith Cummins)]

I call the shadow Minister.

--- Later in debate ---

[The Parliamentary Under-Secretary of State for Health and Social Care (Ashley Dalton)]

I thank my hon. Friend the Member for Mitcham and Morden (Dame Siobhain McDonagh) and the hon. Member for Witney (Charlie Maynard) for securing this vitally important debate. They have both been powerful voices in this place for more research, greater care and better treatments for patients with brain tumours. My hon. Friend spoke so powerfully, as always, and in the name of her sister Margaret. I thank the hon. Member for Witney for sharing his sister’s story. I commend her for her fundraising activity and wish her the very best. The hon. Member asked three very clear questions, which I hope my response will cover.

I also thank other Members who made powerful contributions in what has been a very constructive debate. I hope my responses will answer their queries, but if not, I will endeavour to write to all Members following this debate about any gaps that are left. The hon. Member for Edinburgh West (Christine Jardine) spoke about disparity of drug access. My right hon. Friend the Member for Hayes and Harlington (John McDonnell) asked for zest, and spoke about the requirement for it. He expressed the frustrations of the APPG and others at the speed at which we are able to make progress. The hon. Member for Strangford (Jim Shannon) spoke about the importance of research, and my hon. Friend the Member for Bolton West (Phil Brickell) spoke about clinical trials. The hon. Member for Leicester South (Shockat Adam) brought his expertise on optometry to bear, and spoke about how useful an eye test can be. The hon. Member for North Shropshire (Helen Morgan), the Liberal Democrat spokesperson, talked about low-grade tumours. I commend her constituents, whom she spoke about, for their work.

I thank the shadow Minister, the hon. Member for Hinckley and Bosworth (Dr Evans), for sharing the story of Isla’s stones. What a powerful metaphor and a powerful remembrance. He also spoke about the acquired brain injury strategy. My remarks will focus on brain tumours, but I can confirm that the ABI strategy remains in play and in development. I will update the House on that as soon as possible. First, I pay tribute to some fantastic charities for their advocacy—the Brain Tumour Charity, Brain Tumour Research, Cancer Research UK and Tom’s Trust, to name just a few.

Innovative research is vital in our fight against this devastating disease if we are to offer people the most cutting-edge treatments and the highest-quality care. The Department of Health and Social Care, through the National Institute for Health and Care Research, invests over £1.6 billion per year in research. In the past financial year alone, it invested over £130 million specifically in cancer research. That has enabled 261 brain tumour studies to happen in the NHS, involving 11,400 people in potentially life-changing research over the past six years. Since 2018, the NIHR has directly invested almost £12 million in brain tumour research projects; it has also spent around £37.5 million on wider infrastructure investments in facilities, services and the research workforce, making research possible. In addition, over five years, between 2020 and 2024, the Medical Research Council committed more than £18.5 million to brain tumour research.

Our investments are having an impact. NIHR-funded research has shown that a new targeted drug combination treatment can give better outcomes for one of the most common types of paediatric brain cancer, but of course there is still so much more to do. Too little is known about how to prevent, diagnose and manage brain tumours, and they remain one of the hardest cancers to treat and a challenging area for research. That is why we are committed to furthering our investment in brain cancer research and have already taken some steps to stimulate scientific progress. I would like to offer the House just three examples from the past year.

First, in September, the NIHR announced a new package of funding opportunities for brain cancer research for both adults and children. Secondly, in December, the NIHR established a new national brain tumour research consortium. The consortium brings together research from a range of disciplines and institutions to drive faster scientific advancements in how we prevent, detect, manage and treat brain cancer. This complements the NIHR’s dedicated funding call on research into wraparound care, rehabilitation and quality of life for patients with brain tumours. It has received a high volume of applications, and those applications are under consideration by an independent expert peer review panel.

Thirdly, the Department is working actively as a member of the Tessa Jowell Brain Cancer Mission to fully support the vision of bringing the best care to all brain tumour patients in the UK. Together, we will work with the brain tumour community to accelerate research and bring new insights to the field. This summer, the mission will launch the Tessa Jowell allied health professional research fellowship to train early-career health professionals in conducting vital research on how we improve patients’ quality of life.

The commitment to spend at least £40 million on brain cancer remains in place. The limiting factor has not been restrictions on funding, or funds being spent elsewhere, and every research proposal assessed as being fundable has been funded. My Department is now focusing on how we grow the scientific community working on brain cancer to get more research funded. We are committed to increasing spending on brain cancer research, and the £40 million target is not a funding ceiling—it will not end there. However, it is important that only high-quality applications be funded, so that public funds are invested well and produce impactful and usable research evidence. We will continue to work hand in glove with partners who fund research on new scientific discoveries, such as Cancer Research UK, the Medical Research Council and brain tumour charities. We stand ready to translate these much-needed discoveries as quickly as possible into new treatments for patients via the NIHR.

My hon. Friend the Member for Mitcham and Morden raised the issue of partnerships with industry to develop treatments, and I can confirm that we are committed to working with the pharmaceutical industry and others with the common aim of creating a faster, more efficient, more accessible and innovative clinical treatment delivery system. We expect these efforts to attract more commercial investment in clinical research, and to yield a broad and diverse portfolio of clinical trials in the UK, so that we can provide innovative treatment options for patients, including those with glioblastoma. The new brain tumour research consortium, to which I have referred, will bring together people to work on that, and will work to detect, manage and treat rarer and less survivable cancers in children and adults.

Clinical trials are a crucial part of cancer research. They are the key to advanced medical progress, improved patient outcomes and more hope for the future. Britain is already one of the best destinations in the world for clinical trials, but we want to go further. On 7 April, the Prime Minister announced action to accelerate the set-up and delivery of clinical trials; the time taken to set up studies will be cut to 150 days by March next year, down from 250 days, according to the latest data, which was collected in 2022.

The Department of Health and Social Care is committed to being a world-leading destination for clinical trials. Work is ongoing to streamline and reform the set-up and delivery of clinical trials through digitalisation, and by reducing unnecessary bureaucracy. That is driving a “right research, right setting” initiative, and we are moving from reactive to proactive portfolio management, including by supporting the workforce and continuing to embed a research and innovation culture across the health and social care system.

The Government also support the private Member’s Bill on rare cancers, brought forward by my hon. Friend the Member for Edinburgh South West (Dr Arthur). The Bill will make it easier for clinical trials on rare cancers to take place in England by ensuring that the patient population can be easily contacted.

This Government are committed to backing innovative clinical research ecosystems in the UK, so that British patients can be among the first to benefit. We will bust bureaucracy, fast-track clinical trials and give patients improved access to cutting-edge treatments and technologies, including for brain tumours. “Be Part of Research” is our landmark service, allowing people from all walks of life across the UK to find and participate in research relevant to them, which could transform lives. I urge everybody watching at home to sign up to “Be Part of Research” and to get involved.

We have spoken about medicines repurposing, whereby medicines approved for a particular condition are used in new ways to treat different conditions. Repurposing drugs may have particular value for rare cancers, such as brain cancers, for which drug development has been limited. As my hon. Friend the Member for Mitcham and Morden noted, NHS England has suspended its medicines repurposing programme, but not because it is unimportant; it has shown that opportunities to use existing medicines in new ways can be delivered without the support of a formal repurposing programme, including, for example, through local off-label prescribing. This creates opportunities for NIHR and other funders to support proposals for clinical trials that use repurposed drugs for rare cancers. We will help researchers work with industry and clinicians to strengthen the evidence base for new drugs, and for new uses of drugs, so that we can find out how patients can best be helped.

[Helen Morgan]

How well will that work be co-ordinated if it is done on a local, sporadic basis, and how will the repurposing of drugs be co-ordinated centrally if NHS England is no longer undertaking that work?

[Ashley Dalton]

NHS England has found that creating that environment does not necessarily provide new and better ways of repurposing drugs, and that can be done far more efficiently and far less bureaucratically by using local off-label prescribing. We are looking at how we can incentivise researchers and clinical trials to explore repurposing drugs.

We are determined to make the NIHR and other funders grasp opportunities to support those proposals. We will help researchers work with industry and clinicians to strengthen the evidence base for new drugs.

The NHS is working hard to diagnose and treat cancers on time. There is more to do on early diagnosis and faster treatment, in order to improve patient experience and survival. The NHS is focused on improving diagnostic waiting times, and on providing MRI, CT and other tests to reduce cancer waits, because, as Lord Darzi’s investigation has shown, we face significant challenges if we are to bring this country’s cancer survival rates back up to the standard of the best in the world. We know that the best way to improve survival for those with brain tumours, and with all cancers, is to diagnose patients early and treat them quickly.

In our first six months, 80,000 more patients received a diagnosis or an all-clear within 28 days than did in the previous year, thanks to investment in cutting NHS waiting lists. In March, more than 80% of patients in England referred for cancer had it ruled out or diagnosed within 28 days—it is the first time that target has been met in years—but we must go further, and we will. Our reforms to cancer care will see more than 100,000 people diagnosed faster, and thousands more starting treatment within two months across the NHS.

There is no single solution to this complex challenge. That is why my right hon. Friend, the Secretary of State, has been clear that there will be a national cancer plan published later this year. This plan will ensure that rarer cancers, including brain cancers, will not be left behind. It is my absolute privilege, as a person with cancer, to be driving that cancer plan. I am delighted that we have so far received more than 11,000 representations as part of the call for evidence. I can assure my hon. Friend the Member for Mitcham and Morden that her contributions and all others will be taken seriously.

The Liberal Democrat spokesperson also talked about low-grade cancers. There is a difference between staging and grading, and it is important that we are clear about that. Low-grade brain tumours are considered non-cancerous, and they grow more slowly and are less likely to spread, but although low-grade brain tumours are generally non-cancerous, they can have similar serious symptoms, and require surgery or radiotherapy to treat them. The Government are investing in new life-saving and life-improving research to support people diagnosed with those cancers.

In closing, for those affected by this devastating disease, every discovery, every treatment and every moment matters. We recognise that more needs to be done to stimulate high-quality, high-impact research into brain tumours. Through our targeted package of support, that is what we will do. We completely understand the strength of feeling on this issue, not least because three Ministers in the Department of Health and Social Care are cancer survivors. We know how terrifying it is to receive a diagnosis. We have sat in waiting rooms, hoping for good news and fearing the worst—and we have heard the worst. We have had those difficult conversations with our loved ones and seen the devastating impact on their lives. That is why we are committed to making a real difference for patients with brain cancer. We will leave no stone unturned until they get the first-class care that they deserve. I look forward to further discussing how we can achieve this when I meet members of the all-party parliamentary group on brain tumours next week.